The company’s revenue was up 19.3% compared to the same quarter past year.
Advertisement
Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. (NYSE:PFE) rose +1.14% in trading session and finally closed at $37.31. The company traded 28.38 million shares versus it average capacity of 24.47 million shares. The company has a market capitalization of $221.00 billion and a price-to-earnings ratio of 29.87.
Pfizer Inc. (NYSE:PFE) reached at $37.31 price level during last trade its distance from 20 days simple moving average is 2.37%, and its distance from 50 days simple moving average is 5.63% while it has a distance of 15.25% from the 200 days simple moving average. SunTrust Banks also issued estimates for Pfizer’s Q3 2016 earnings at $0.58 EPS. Company is -31.90% away from its 52 week high and is moving 3.26% ahead of its 52 week low.
The drugmaker posted revenue of $13.15 billion in the period, also exceeding Street forecasts. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million.
It was reached almost seven years after Pfizer agreed in September 2009 to pay $2.3 billion to settle a US government probe into the marketing of Bextra and other drugs. This represents a $1.20 annualized dividend and a yield of 3.22%.
The average estimate of EPS for the current financial quarter, company stands at $0.62 while the Earning per share for the current fiscal year is fixed at $2.45 by 17 analysts.
Canandaigua National Bank Trust Co scooped up 3,300 additional shares in Pfizer during the most recent quarter end, the firm said in a disclosure report filed with the SEC on Jul 26, 2016. HGK Asset Management Inc. increased its stake in Pfizer by 1,395.5% in the fourth quarter. Morgan Stanley initiated coverage on shares of Pfizer in a research report on Thursday, April 7th. Jefferies Group reissued a “buy” rating and set a $39.00 price objective (down previously from $42.00) on shares of Pfizer in a research report on Tuesday, April 5th. 8 analysts have rated the company as a strong “Hold”. The company presently has a consensus rating of “Buy” and a consensus price target of $38.28.
In other news, insider Mikael Dolsten sold 67,588 shares of Pfizer stock in a transaction on Wednesday, May 4th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The stock was sold at an average price of $33.80, for a total value of $9,295,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,446,738 shares in the company, valued at approximately $48,899,744.40.
For an overview of the company, read Investing in Pfizer?
Advertisement
In August, Pfizer acquired all remaining equity in Bamboo Therapeutics, a privately held biotechnology company focused on developing gene therapies for the treatment of patients with certain rare diseases, for an upfront payment of $150 million plus potential milestone payments to Bamboo’s selling shareholders of up to $495 million. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare.
